Ссылки
1.Tanne J. H. Merck appeals rofecoxib verdict. BMJ. 2007; 334: 607.
2.Lenzer J. FDA is incapable of protecting US ‘against another Vioxx’. BMJ. 2004; 329: 1253.
3.Krumholz H. M., Ross J. S., Presler A. H., et al. What have we learned from Vioxx? BMJ. 2007; 334: 120–3.
4.Topol E. J. Failing the public health – rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351: 1707–9.
5.Petersen M. Our Daily Meds. New York: Sarah Crichton Books;
2008.
6.Jüni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021–9.
7.Graham D. J. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006; 296: 1653–6.
8.Topol E. Arthritis medicines and cardiovascular events – ‘house of coxibs’. JAMA. 2005; 293: 366–8.
9.Psaty B. M., Furberg C. D. COX-2 inhibitors – lessons in drug safety. N Engl J Med. 2005; 352: 1133–5.
10.US Senate Finance Committee. Testimony of David J Graham, MD, MPH. 2004 Nov 18. Available online at: www.finance.senate.gov/imo/media/doc/111804dgtest.pdf (accessed 21 February 2013).
11.US Food and Drug Administration. Memorandum. 2001. Available online at: www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf (accessed 23 June 2009).
12.Weaver A. L., Messner R. P., Storms W. W., et al. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. J Clin Rheumatol. 2006; 12: 17–25.
13.Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343: 1520–8.
14.Armstrong D. The New England Journal missed Vioxx warning signs. 2006 May 15. Available online at: www.post- gazette.com/pg/06135/690336-114.stm (accessed 27 November 2012).
15.Curfman G. D., Morrissey S., Drazen J. M. Expression of concern reaffirmed. N Engl J Med. 2006. 10.1056/NEJMe068054. Accessed 23 Feb 2006.
16.Curfman G. D., Morrissey S., Drazen J. M. Expression of concern: Bombardier et al., ‘Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,’ N Engl J Med 2000;343:1520–8. N Engl J Med. 2005; 353: 2813–14.
17.Mukherjee D., Nissen S. E., Topol E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001; 286: 954– 9.
18.Liévre M., Abadie E., on behalf of the French Marketing Authorization Committee. Discontinuation of Vioxx. Lancet. 2005; 365: 23– 4.
19.Konstam M. A., Weir M. R., Reicin A. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001; 104: 2280-8.
20.Reicin A. S., Shapiro D., Sperling R. S., et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002; 89: 204–9.
21.Corporate sponsorship. American Heart Association. Updated 2012
Oct 25. Available online at: www.heart.org/HEARTORG/Giving/ForCompanies/SponsorshipOpportuniti es/Corporate-Sponsorship_UCM_321431_Article.jsp (accessed 31 October 2012).
22.Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.
23.Sanon S., Patel R., Eshelbrenner C., et al. Acute coronary syndrome in patients with diabetes mellitus: perspectives of an interventional cardiologist. Am J Cardiol. 2012; 110 supplement: 13B–23B.
24.Hill K. P., Ross J. S., Egilman D. S., et al. The ADVANTAGE seeding trial: a review of internal docu-ments. Ann Intern Med. 2008; 149: 251–8.
25.Lisse J. R., Perlman M., Johansson G., et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003; 139: 539–46.
26.Berenson A. Evidence in Vioxx suits shows intervention by Merck officials. New York Times. 2005 Apr 24.
27.Ross J. S., Hill K. P., Egilman D. S., et al. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008; 299: 1800–2.
28.Jørgensen A. W., Jørgensen K. J., Gøtzsche P. C. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. Eur J Clin Pharmacol. 2010; 66: 341–7.
29.Grant B. Merck published fake journal. The Scientist. 2009. Available online at: www.the-scientist.com/blog/display/55671 (accessed 23 June 2009).
30.Day M. Don’t blame it all on the bogey. BMJ. 2007; 334: 1250–1.
31.Psaty B. M., Furberg C. D. COX-2 inhibitors – lessons in drug safety. N Engl J Med. 2005; 352: 1133–5.
32.Waxman H. A. The lessons of Vioxx – drug safety and sales. N Engl J Med. 2005; 352: 2576–8.
33.Waxman H. A. The marketing of Vioxx to physicians. Memorandum. Congress of the United States. 2005 May 5.
34.Frazier K. C. The lessons of Vioxx. N Engl J Med. 2005; 353:
1420.
35.Waxman H. A. The lessons of Vioxx. N Engl J Med. 2005; 353:
1420–1.
36.Kim P. S., Reicin A. S. Rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351: 2875–6.
37.Bresalier R. S., Sandler R. S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092–102.
38.Nissen S. E. Adverse cardiovascular effects of rofecoxib. N Engl J Med. 2006; 355: 203–4.
39.Correction. N Engl J Med. 2006; 355: 221.
40.Topol E. Rofecoxib, Merck, and the FDA. N Engl J Med. 2004; 351:
2877–8.
41.Psaty B. M., Kronmal R. A. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008; 299: 1813–17.
42.Madigan D., Sigelman D. W., Mayer J. W., et al. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart
J.2012; 164: 186–93.
43.Juhlin R. [MSD about Vioxx]. Läkartidningen. 2004; 46: 3720–1.
44.Whelton R. S. Effects of excessive CEO pay on U. S. society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007).
45.Department of Justice. U. S. pharmaceutical company Merck Sharp & Dohme sentenced in connection with unlawful promotion of Vioxx. 2012 April 19.
46.Charatan F. 94 % of patients suing Merck over rofecoxib agree to terms. BMJ. 2008; 336: 580–1.
47.Berenson A. Merck agrees to settle Vioxx suits for $485. billion. New York Times. 2007 Nov 9.